BD Innovation For Subcutaneous Delivery Of Large-Volume Complex Biologics

By Beth McBride DiLauri, Director, Portfolio Marketing, BD Medical – Pharmaceutical Systems

For individuals with chronic illnesses like diabetes and obesity, managing medication can be a constant burden. New wearable injector technology is emerging to address this challenge, offering a more convenient and comfortable approach to treatment.

This study explores the BD Libertas Wearable Injector, a novel device designed for self-administered subcutaneous injections at home or in clinical settings. The injector prioritizes patient experience by eliminating the need for assembly or filling, and features automated needle insertion and retraction for a more user-friendly experience.

Clinical studies investigating the BD Libertas Wearable Injector confirm its safety, usability, and high patient acceptance. The injector offers several advantages over traditional intravenous (IV) administration, including increased patient autonomy, reduced treatment burden, and the potential for self or caregiver injection.

In this article, Beth McBride DiLauri, Director, Portfolio Marketing at BD Medical – Pharmaceutical Systems, explores the key findings of the BD Libertas Wearable Injector clinical trial, highlighting its positive impact on patient experience. Additionally, the broader benefits of wearable injectors for chronic disease management are discussed.